Granules India
Granules India Ltd is an Indian multinational pharmaceutical manufacturing enterprise specializing in the research, development, production, and global wholesale distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosage formulations (FDFs), prominently featuring high-volume analgesic, anti-diabetic, anti-coagulant, and anti-infective drug products supplied to global pharmaceutical brands and healthcare distributors across North America, Europe, Latin America, and Asia. The company operates advanced USFDA-compliant chemical synthesis and finished dosage manufacturing complexes in India. Its core business operations encompass API synthesis, pharmaceutical intermediate manufacturing, finished dosage formulation, and international wholesale distribution. Revenue is derived directly from the global wholesale sale of APIs and pharmaceutical formulations to global drug manufacturers. Granules India holds a leading global market position in high-volume pharmaceutical active ingredients and finished dosage manufacturing. The company is headquartered in Hyderabad, Telangana, India, and its equity shares trade on the National Stock Exchange of India and BSE Limited.
2 of the funds FundTelligence covers report a position in Granules India.
- Legal name
- Granules India Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 2
Funds holding Granules India
- Schroder ISF Global Emerging Markets Smaller Companies — Schroders · 0.7 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)